{"disease":{"id":"fabry-disease","name":"fabry disease"},"drugs":{"marketed":[{"drug_id":"agalsidase-beta","indication_name":"Fabry's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fabrazyme","generic_name":"AGALSIDASE BETA","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"","drug_class":"Hydrolytic Lysosomal Neutral Glycosphingolipid-specific Enzyme [EPC]","quality_score":59,"revenue":"1000","mechanism":"Fabrazyme works by replacing the deficient enzyme alpha-Gal A to break down and remove toxic globotriaosylceramide."},{"drug_id":"pegunigalsidase-alfa","indication_name":"Fabry's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Elfabrio","generic_name":"PEGUNIGALSIDASE ALFA","company_name":"Chiesi Farmaceutici S.P.A","drug_phase":"marketed","molecular_target":"","drug_class":"Hydrolytic Lysosomal Neutral Glycosphingolipid-specific Enzyme [EPC]","quality_score":50,"revenue":null,"mechanism":"Elfabrio works by reducing the accumulation of a specific lipid in the body."},{"drug_id":"fabrazyme-agalsidase-beta","indication_name":"Treatment of adult and pediatric patients 2 years of age and older with confirmed Fabry disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Fabrazyme (agalsidase beta)","company_name":"Genzyme, a Sanofi Company","drug_phase":"marketed","molecular_target":"α-galactosidase A (GLA gene product); substrate: globotriaosylceramide (GL-3)","drug_class":"Enzyme replacement therapy (ERT); recombinant enzyme","quality_score":26,"revenue":null,"mechanism":""},{"drug_id":"pegunigalsidase-alfa-iwxj","indication_name":"Fabry's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"ELFABRIO","generic_name":"PEGUNIGALSIDASE ALFA-IWXJ","company_name":"CHIESI FARMACEUTICI SPA","drug_phase":"marketed","molecular_target":"","drug_class":"Hydrolytic Lysosomal Neutral Glycosphingolipid-specific Enzyme [EPC]","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"agalsidase-alfa","indication_name":"Fabry's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Replagal","generic_name":"AGALSIDASE ALFA","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"migalastat","indication_name":"Fabry's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Galafold","generic_name":"MIGALASTAT","company_name":"Amicus Therap Us","drug_phase":"marketed","molecular_target":"Alpha-galactosidase A","drug_class":"","quality_score":65,"revenue":null,"mechanism":"Galafold stabilizes the alpha-galactosidase A enzyme to treat Fabry's disease."},{"drug_id":"replagal","indication_name":"Fabry's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Replagal","company_name":"National Institute of Neurological Disorders and Stroke (NINDS)","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":9,"revenue":null,"mechanism":null},{"drug_id":"agalsidase","indication_name":"Fabry's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"agalsidase","company_name":"Amicus Therapeutics","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":8,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05368038","title":"ScreenPlus: A Comprehensive, Flexible, Multi-disorder Newborn Screening Program","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":100000,"lead_sponsor_name":"Albert Einstein College of Medicine","has_results":false},{"nct_id":"NCT06065852","title":"National Registry of Rare Kidney Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":35000,"lead_sponsor_name":"UK Kidney Association","has_results":false},{"nct_id":"NCT06607471","title":"Multimodal and Multidisciplinary Approach to Optimize Diagnostic, Prognostic, and Therapeutic Management of Patients with Non-ischemic Cardiomyopathies and Arrhythmogenic-inflammatory Phenotypes: a Multicenter, Observational, Retrospective and Prospective Registry Study.","phase":"","overall_status":"RECRUITING","enrollment_count":15000,"lead_sponsor_name":"Scientific Institute San Raffaele","has_results":false},{"nct_id":"NCT00196742","title":"Fabry Disease Registry & Pregnancy Sub-registry","phase":"","overall_status":"RECRUITING","enrollment_count":9000,"lead_sponsor_name":"Genzyme, a Sanofi Company","has_results":false},{"nct_id":"NCT03289065","title":"Fabry Outcome Survey (FOS)","phase":"","overall_status":"COMPLETED","enrollment_count":4000,"lead_sponsor_name":"Shire","has_results":false},{"nct_id":"NCT01019629","title":"Fabry Screening Study","phase":"","overall_status":"COMPLETED","enrollment_count":2724,"lead_sponsor_name":"Baylor Research Institute","has_results":false},{"nct_id":"NCT05056636","title":"Epidemiological Study of Fabry Disease Screening in Chronic Kidney Disease Patients","phase":"","overall_status":"UNKNOWN","enrollment_count":2000,"lead_sponsor_name":"Chang Gung Memorial Hospital","has_results":false},{"nct_id":"NCT03596398","title":"Epidemiological Study of Fabry Disease in Taiwan Young Stroke Patients","phase":"","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"Chiayi Christian Hospital","has_results":false},{"nct_id":"NCT07336394","title":"Precision Diagnosis and Risk Stratification of Rare Cardiomyopathies Based on Novel Cardiac Magnetic Resonance Techniques","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Chinese Academy of Medical Sciences, Fuwai Hospital","has_results":false},{"nct_id":"NCT06806813","title":"Italian Anderson Fabry Disease Cardiovascular Registry","phase":"","overall_status":"RECRUITING","enrollment_count":800,"lead_sponsor_name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","has_results":false},{"nct_id":"NCT02450604","title":"Prevalence of Fabry's Disease in a Population of Patients With Chronic Pain","phase":"NA","overall_status":"COMPLETED","enrollment_count":776,"lead_sponsor_name":"University Hospital, Bordeaux","has_results":false},{"nct_id":"NCT06813443","title":"Characterization of Patients With Cardiomyopathy to Identify Critical Patients Candidates for Cardiac Transplantation","phase":"","overall_status":"RECRUITING","enrollment_count":700,"lead_sponsor_name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","has_results":false},{"nct_id":"NCT06169358","title":"Screening Patients With Fabry Disease in Patients With Hypertrophic Cardiomyopathy or Left Ventricular Hypertrophy","phase":"","overall_status":"UNKNOWN","enrollment_count":627,"lead_sponsor_name":"Qilu Hospital of Shandong University","has_results":false},{"nct_id":"NCT03886714","title":"Screening for Fabry Disease in Renal Transplantation","phase":"","overall_status":"TERMINATED","enrollment_count":592,"lead_sponsor_name":"University Hospital, Montpellier","has_results":false},{"nct_id":"NCT06935578","title":"RAre, But Not aLone: a Large Italian Network to Empower the Impervious diaGNostic Pathway of Rare cerEbrovascular Diseases (ALIGNED)","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta","has_results":false},{"nct_id":"NCT05473637","title":"Taiwan Associated Genetic and Nongenetic Small Vessel Disease","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"National Taiwan University Hospital","has_results":false},{"nct_id":"NCT05409846","title":"Screening of Fabry Disease in Portuguese Patients With Idiopathic Cardiomyopathies","phase":"","overall_status":"COMPLETED","enrollment_count":409,"lead_sponsor_name":"Universidade do Porto","has_results":false},{"nct_id":"NCT03199001","title":"Native T1 Mapping by Cardiovascular Magnetic Resonance Imaging in Rare Diseases","phase":"","overall_status":"UNKNOWN","enrollment_count":400,"lead_sponsor_name":"University College, London","has_results":false},{"nct_id":"NCT03230149","title":"Prevalence and Characteristics of Fabry Disease (FD) in Patients With Stroke or Small Fiber Neuropathy","phase":"","overall_status":"COMPLETED","enrollment_count":379,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT03321604","title":"Kidney Information Network for Disease Research and Education","phase":"","overall_status":"TERMINATED","enrollment_count":338,"lead_sponsor_name":"Massachusetts General Hospital","has_results":false},{"nct_id":"NCT00001491","title":"Analysis of the Nervous System in Patients With Fabry's Disease","phase":"","overall_status":"COMPLETED","enrollment_count":325,"lead_sponsor_name":"National Institute of Neurological Disorders and Stroke (NINDS)","has_results":false},{"nct_id":"NCT06512571","title":"CVI Alterations in FD: a Prospective, Multicenter, Observational Cohort Study","phase":"","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"China National Center for Cardiovascular Diseases","has_results":false},{"nct_id":"NCT04856059","title":"Fabry Cardiomyopathy: Identification of Early Myocardial Structural and Tissue Abnormalities Using Multiparametric MRI","phase":"NA","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"University Health Network, Toronto","has_results":false},{"nct_id":"NCT07382128","title":"Myocardial Perfusion CMR for Differentiating and Characterizing Hypertrophic Cardiomyopathy Phenotypes","phase":"","overall_status":"RECRUITING","enrollment_count":250,"lead_sponsor_name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","has_results":false},{"nct_id":"NCT04943991","title":"Fabry Disease in High-risk Patients With Left Ventricular Hypertrophy: Prevalence and Implementation of a Clinical Score","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":200,"lead_sponsor_name":"Wuerzburg University Hospital","has_results":false},{"nct_id":"NCT07187440","title":"A Study of Agalsidase Alfa Enyzme Replacement Therapy in Chinese Children and Adults With Fabry Disease","phase":"","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Takeda","has_results":false},{"nct_id":"NCT04708301","title":"Characterisation of Heart Involvement in Fabry Disease With T1 Mapping","phase":"","overall_status":"COMPLETED","enrollment_count":200,"lead_sponsor_name":"Manchester University NHS Foundation Trust","has_results":false},{"nct_id":"NCT04916977","title":"Global Burden and Treatment Trajectiories in Italian Patients With Fabry Disease","phase":"","overall_status":"COMPLETED","enrollment_count":200,"lead_sponsor_name":"Chiesi Italia","has_results":false},{"nct_id":"NCT06956573","title":"Aortic Dimensions in Patients With Fabry Disease","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":200,"lead_sponsor_name":"University Hospital, Caen","has_results":false},{"nct_id":"NCT04184986","title":"Screening of Fabry Disease in Patients With GI Symptoms","phase":"","overall_status":"UNKNOWN","enrollment_count":200,"lead_sponsor_name":"General University Hospital, Prague","has_results":false},{"nct_id":"NCT01298141","title":"A Multicenter Open-Label Treatment Protocol to Observe the Safety of Replagal (Agalsidase Alfa) Enzyme Replacement Therapy in Canadian Patients With Fabry Disease","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":171,"lead_sponsor_name":"Shire","has_results":true},{"nct_id":"NCT05761834","title":"FASHION Fabry Disease Hypertrophic Cardiomyopathy and Infammation","phase":"","overall_status":"UNKNOWN","enrollment_count":150,"lead_sponsor_name":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","has_results":false},{"nct_id":"NCT04758130","title":"Getting Global Rare Disease Insights Through Technology Study","phase":"NA","overall_status":"UNKNOWN","enrollment_count":150,"lead_sponsor_name":"M.A.G.I.C. Clinic LTD","has_results":false},{"nct_id":"NCT05698901","title":"Biomarkers and Cardiac Imaging Diagnostic Assay for Monitoring Patients With Fabry Disease","phase":"","overall_status":"RECRUITING","enrollment_count":150,"lead_sponsor_name":"Mackay Memorial Hospital","has_results":false},{"nct_id":"NCT01355146","title":"Home Therapy With Replagal in Fabry Disease","phase":"","overall_status":"COMPLETED","enrollment_count":127,"lead_sponsor_name":"Shire","has_results":false},{"nct_id":"NCT05206773","title":"A Study to Evaluate the Effect of Venglustat Tablets on Neuropathic and Abdominal Pain in Male and Female Participants ≥16 Years of Age With Fabry Disease","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":122,"lead_sponsor_name":"Sanofi","has_results":false},{"nct_id":"NCT03425539","title":"Efficacy and Safety of Lucerastat Oral Monotherapy in Adult Subjects With Fabry Disease","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":118,"lead_sponsor_name":"Idorsia Pharmaceuticals Ltd.","has_results":true},{"nct_id":"NCT06303466","title":"Real World Evidence Study of Danish Fabry Patients","phase":"","overall_status":"UNKNOWN","enrollment_count":115,"lead_sponsor_name":"Caroline Michaela Kistorp","has_results":false},{"nct_id":"NCT05046379","title":"Studying Lipids as Potential Biomarkers in Patients With Fabry Disease","phase":"","overall_status":"COMPLETED","enrollment_count":108,"lead_sponsor_name":"Vastra Gotaland Region","has_results":false},{"nct_id":"NCT05280548","title":"A Study to Evaluate the Effect of Venglustat Tablets on Left Ventricular Mass Index in Male and Female Adult Participants With Fabry Disease","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":104,"lead_sponsor_name":"Sanofi","has_results":false},{"nct_id":"NCT07277361","title":"Study of the Quality of Life of Patients With Fabry Disease Aged 65 and Over With and Without Specific Treatment","phase":"","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Wladimir MAUHIN, Dr","has_results":false},{"nct_id":"NCT00055016","title":"Registry of Fabry Disease - A Multicenter Observational Study","phase":"","overall_status":"COMPLETED","enrollment_count":100,"lead_sponsor_name":"National Institute of Neurological Disorders and Stroke (NINDS)","has_results":false},{"nct_id":"NCT06484478","title":"A Real-world Wearables Study in Fabry Disease.","phase":"","overall_status":"COMPLETED","enrollment_count":100,"lead_sponsor_name":"Royal Free Hospital NHS Foundation Trust","has_results":false},{"nct_id":"NCT03566017","title":"Open Label Extension Study of 1 mg/kg Pegunigalsidase Alfa Every 2 Weeks in Patients With Fabry Disease","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":97,"lead_sponsor_name":"Chiesi Farmaceutici S.p.A.","has_results":true},{"nct_id":"NCT01458119","title":"Open-Label Phase 3 Long-Term Safety Study of Migalastat","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":85,"lead_sponsor_name":"Amicus Therapeutics","has_results":true},{"nct_id":"NCT02194985","title":"Open-Label Extension Study of the Long-Term Effects of Migalastat HCL in Patients With Fabry Disease","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":84,"lead_sponsor_name":"Amicus Therapeutics","has_results":true},{"nct_id":"NCT04281537","title":"A Study to Describe the Experience of Both Patients and Their Clinicians in the Treatment of Fabry Disease With Enzyme Replacement Therapy.","phase":"","overall_status":"COMPLETED","enrollment_count":82,"lead_sponsor_name":"Amicus Therapeutics","has_results":true},{"nct_id":"NCT06801288","title":"Diagnostic Role of Renal Biopsy in Patients With Fabry Disease","phase":"","overall_status":"COMPLETED","enrollment_count":80,"lead_sponsor_name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","has_results":false},{"nct_id":"NCT03222336","title":"Natural History in Fabry Patients With IVS4+919G>A Mutation","phase":"","overall_status":"UNKNOWN","enrollment_count":80,"lead_sponsor_name":"Taipei Veterans General Hospital, Taiwan","has_results":false},{"nct_id":"NCT06052800","title":"Agalsidase Beta Long-Term Treatment Outcome for Fabry Disease Patients With IVS4 Mutation in Taiwan","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":78,"lead_sponsor_name":"Sanofi","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}